Press Release: Imcyse : Imcyse Announces First Patient Dosed in Adaptive Phase 1/2 Clinical Trial of Imotope IMCY-0141 for Multiple Sclerosis

LIÈGE, Belgium, April 13, 2022 (GLOBE NEWSWIRE) -- Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new class of active and specific immunotherapies for the treatment of severe autoimmune diseases, today announced the first patient has been dosed in the adaptive Phase 1/2 clinical trial evaluating ImotopeTM IMCY-0141 in patients with relapsing-remitting multiple sclerosis (RRMS). Subject to meeting the planned recruitment milestones, Imcyse expects to report interim results in Q4 2023.